United States kidney function
test market is expected to grow significantly over the coming years, due to
major factors. These factors include the rising prevalence of chronic kidney
diseases, increasing awareness about the importance of early diagnosis and
treatment, and technological advancements in testing methods.
According to CDC (Centre for
Disease Control and Prevention), more than 1 in 7, that is 15% of US adults or
37 million people, are estimated to have chronic kidney disease.
The importance of early kidney
disease diagnosis and detection has resulted in a significant increase in
public awareness. Frequent kidney function tests have been rapidly promoted by
medical professionals and health organizations to identify problems with renal
function early on. Early detection enables prompt care, which slows the
progression of the disease and improves patient outcomes. The demand for kidney
function testing has increased in the United States due to the focus on
preventative healthcare treatments.
Kidney function tests have been
revolutionized by advancements in diagnostic technologies and testing
procedures. The efficiency, speed, and convenience of conducting these tests
are all improving due to the development of automated analyzers and
point-of-care testing equipment. Technological advancements have further
accelerated the diagnosis process by providing effective data management and
remote monitoring of patients' kidney function, such as the integration of
electronic health records (EHRs) and telehealth services. These technological
developments have improved kidney function test accessibility and price,
spurring market expansion.
The market of kidney function
testing has expanded substantially because of the ageing population in the
United States. The kidney function of the elderly must be regularly monitored
because they are more susceptible to renal disorders. It is expected that
demand for kidney function testing would rise in parallel with the population's
continued ageing trend.
The market of kidney function
testing in the United States will face a few challenges, though. The
constraints include high costs, restricted reimbursement, a lack of standards,
low awareness, problems with diagnostic accuracy, slow adoption of cutting-edge
technologies, and data privacy issues.
In kidney function tests,
accuracy is crucial. Though, it is possible for test results to be inaccurate
and provide false-positive or false-negative results. The interpretation of
test findings may be impacted by various types of drugs, comorbidities, and
dietary considerations, which may result in a false diagnosis or poor treatment
options. To keep patients' and healthcare professionals' trust and confidence,
it is essential to increase the precision of kidney function tests, reduce
erroneous results, and create procedures that take confounding factors into
account.
Data security and privacy are
significant concerns because of the expanding usage of electronic health
records (EHRs) and digital platforms for storing and sharing patient
information. To ensure patient confidentiality, it is necessary to implement
strong data protection procedures due to the sensitive nature of kidney
function test results. To foster trust and promote the broad use of kidney
function testing, strict data privacy legislation must be put in place, as well
as secure information-sharing networks.
The field of diagnostics,
especially kidney function testing, is undergoing a revolution due to the
integration of artificial intelligence (AI) and machine learning (ML)
technology. Large datasets can be analyzed by AI and ML systems, which can spot
patterns that human observers would overlook. This innovative data analytics
allows precise diagnostics, early kidney disease detection, and personalized
therapy planning. The use of AI and ML in kidney function tests is expected to
grow as they develop, improving diagnostic accuracy and efficacy.
The United States Food and
Drug Administration (FDA) granted RenalytixAI approval for their new
KidneyIntelX test in August 2020. Clinical trials utilizing AI aim to find
patients with type 2 diabetes and fast deteriorating kidney conditions and to
enhance their therapeutic care. Over the duration of the projected period, the
introduction of technologically improved goods is expected to further drive the
growth of the market.
Novel kidney function tests are
being developed due to advancements in biomarker research. Traditional tests
have drawbacks in terms of sensitivity and specificity, such as serum
creatinine and blood urea nitrogen. Cystatin C, neutrophil gelatinase-associated
lipocalin (NGAL), and kidney injury molecule-1 (KIM-1) are three biomarkers
that have the potential to provide reliable assessments of kidney function and
early indications of damage to the kidneys. The development of biomarker-based
analyses will likely revolutionize the diagnosis of kidney function and enable
accurate and timely detection of renal disorders.
Remote patient monitoring and
telehealth services' adoption has been accelerated by the COVID-19 pandemic,
and these developments are likely to escalate after the outbreak has passed.
With the use of telehealth platforms, medical staff can remotely assess and
monitor patients' kidney function, enabling prompt intervention and lowering
the need for in-person visits. Medical professionals can provide individualized
care and enhance treatment outcomes with the help of remote monitoring
equipment and telehealth services, which provides real-time information on
patients' kidney health.
Growing Prevalence of Chronic
Kidney Diseases
The market of kidney function
tests in the United States is expanding rapidly with the rising prevalence
of chronic kidney diseases. A significant portion of the population is affected
by chronic kidney disease (CKD), which has grown to be a major public health
concern and imposes a heavy burden on healthcare systems as well. Since kidney
function tests are crucial for the early detection, precise diagnosis, and
efficient management of renal disorders, this rise in prevalence has increased
the need for them.
The demand for diagnostic
tests has increased because of the rise in chronic renal diseases. Kidney
function tests are increasingly necessary to evaluate a person's renal health
as more people are identified as having kidney ailments or are at increased
risk for developing them. Serum creatinine, blood urea nitrogen, and estimated
glomerular filtration rate (eGFR) are some examples of the tests that offer
vital information on kidney function and aid in determining the existence and
severity of kidney diseases. Demand for kidney function tests is directly
influenced by the growing number of patients with renal diseases, which is a
factor in the market's expansion.
To be able to effectively manage
chronic kidney diseases, early detection and intervention are essential. Medical
professionals and organizations are emphasizing kidney function tests more
as part of regular health screenings because of a growing awareness of the
significance of early diagnosis. Early detection enables prompt management and
intervention, which can limit the spread of the disease and reduce
complications. The need for kidney function tests is increasing as the
incidence of renal illnesses rises and the value of early detection becomes
increasingly evident.
Growing Prevalence of
Underlying Conditions
The United States kidney function
test market is expanding rapidly, despite the rising incidence of
underlying diseases like diabetes and hypertension that cause complications in
the kidneys. One of the main causes of chronic kidney disease (CKD) globally is
diabetes, and the frequency of both conditions has been gradually rising. There
is a growing need for renal function tests to identify and track kidney damage
related to these underlying disorders as these conditions continue to become
more prevalent in the United States.
The Centres for Disease
Control and Prevention (CDC) reports that 37.3 million population of United
States, or 11.3% of the population, have diabetes. There are 96 million adults
in the United States who are pre-diabetic, or 38.0% of the adult population.
A significant risk factor for the
development of CKD is diabetes. The prevalence of diabetic nephropathy, a form
of kidney injury brought on by diabetes, has increased in tandem with the
rising diabetes prevalence in the United States. To manage diabetic nephropathy
and reduce the severity of CKD, early identification and routine kidney
function monitoring are necessary. The market demand for kidney function tests
is driven by the rising prevalence of diabetes and the growing understanding of
the value of early detection.
Similarly, hypertension, or high
blood pressure, is another important risk factor for renal diseases.
Uncontrolled hypertension can cause the development of hypertensive
nephropathy, a disorder characterized by kidney damage brought on by
persistently high blood pressure. The need for routine renal function tests for
detecting any early indicators of kidney disease is highlighted by the
constantly increasing prevalence of hypertension in the United States.
Kidney function tests are crucial
for identifying persons at risk and treating their renal health because
diabetes, hypertension, and kidney disorders are all intertwined.
Download Free Sample Report
Market Segmentation
The United States kidney function
test market can be segmented by type, component, end user, and region. By type,
the United States kidney function test market can be segmented into urine tests
and blood tests. Based on components, the United States kidney function test
market is divided into dipsticks, reagents, kits & assays, and others.
Based on end user, the United States kidney function test market is divided
into hospitals & clinics, diagnostic laboratories, and others. Based
on region, the United States Kidney function test market is divided into
northeast region, midwest region, south region, and west region.
Market Players
Abbott Laboratories, Quest
Diagnostics, LabCorp, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., and
Sysmex Corporation are some of the leading companies operating in the United
States kidney function test market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2022
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, Volume Units, and CAGR for 2018-2022
and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, Volume forecast company share, competitive landscape, growth
factors, and trends
|
|
Segments
Covered
|
Type
Component
End User
|
|
Regional
Scope
|
Northeast
Region; Midwest Region; South Region; West Region
|
|
Key
Companies Profiled
|
Abbott Laboratories, Quest Diagnostics, LabCorp, F.
Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Corporation
|
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, United States
kidney function test market has been segmented into following categories, in
addition to the industry trends which have also been detailed below:
- United States Kidney Function Test Market, By
Type
- United States Kidney Function Test Market, By
Component
- Dipsticks
- Reagents
- Kits & Assays
- Others
- United States Kidney Function Test Market, By
End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
- United States Kidney Function Test Market, By
Region
- Northeast Region
- Midwest Region
- South Region
- West Region
Competitive Landscape
Company Profiles: Detailed
analysis of the major companies present in United States kidney function test
market.
Available Customizations:
With the given market data,
TechSci Research offers customizations according to a company’s specific needs.
The following customization options are available for the report:
Company Information
Detailed analysis and profiling
of additional market players (up to five).
United States Kidney Function Test Market is an upcoming
report to be released soon. If you wish an early delivery of this report or want
to confirm the date of release, please contact us at [email protected]